### Highlights of This Issue 2193

#### SPECIAL FEATURES

**CCR 20th Anniversary Commentary**

- **CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio**
  Susan E. Bates, Robert W. Robey, and Richard L. Piekaz

- **CCR 20th Anniversary Commentary: Vorinostat—Gateway to Epigenetic Therapy**
  Wm. Kevin Kelly, Paul Marks, and Victoria M. Richon

**CCR Translations**

- **A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2**
  Yanping Xiao and Gordon J. Freeman
  *See related article, p. 2359*

- **Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a "String"**
  Lisa M. Rimsza
  *See related article, p. 2367*

**Molecular Pathways**

- **Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells**
  Hiba Ahmad Zahreddine and Katherine L.B. Borden

**CCR Focus**

- **Quit Early, Quit Often**
  Susan E. Bates

- **Lung Cancer in the Era of Precision Medicine**
  Kateria Politi and Roy S. Herbst

- **EGFR: The Paradigm of an Oncogene-Driven Lung Cancer**
  Gregory J. Riely and Helena A. Yu

- **Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine**
  Ryoei Katayama, Christine M. Lovly, and Alice T. Shaw

- **Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics**
  David R. Gandara, Peter S. Hammerman, Martin L. Sos, Primo N. Lara Jr, and Fred R. Hirsch

- **Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?**
  M. Catherine Pietanza, Lauren Averett Byers, John D. Minna, and Charles M. Rudin

- **Immune Checkpoint Modulation for Non-Small Cell Lung Cancer**
  Jean-Charles Soria, Aurélien Marabelle, Julie R. Brahmer, and Scott Gettinger

**Special Report**

- **Accelerating the Delivery of Patient-Centered, High-Quality Cancer Care**
  Edward Abrahams, Margaret Foti, and Marcia A. Kean

**CANCER THERAPY: CLINICAL**

- **Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer**

- **Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma**
ABOUT THE COVER

The cover shows a section of a bone marrow biopsy from a patient with acute myeloid leukemia (AML). Immunohistochemical staining shows Desert Hedgehog positive osteoblasts underlining the hypothesis of paracrine Hedgehog pathway activation in AML cells. For details, see the article by Wellbrock and colleagues on page 2388 of this issue.